Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

RCC trials are predominantly in high-income countries, limiting access for lower-income patients and affecting global treatment strategies. Minority groups, especially Black and Hispanic ...

A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to ...